Bispecific t-cell engager molecule combinations for use in treatment of claudin18.2 expressing solid tumors

Abstract

(CLDN18.2) binding site and a T cell binding site, in combination with a checkpoint inhibitor agent and / or one or more chemotherapy agent(s), and methods of use therefor. Methods for treating a patient having a CLDN18.2-expressing solid tumor with a bispecific T cell engager (BsTCE), comprising a first domain that binds to CLDN18.2 and a second domain that binds to a T cell, in combination with a checkpoint inhibitor agent and / or one or more chemotherapy agent(s) are disclosed. Also provided are pharmaceutical compositions comprising combinations of a multi-specific T cell engager comprising a CLDN18.2 binding site and a T cell binding site, a checkpoint inhibitor agent, and / or one or more chemotherapy agent(s), such pharmaceutical composition combinations for use in the treatment of a CLDN18.2-expressing cancer, and the use of such pharmaceutical composition combinations for the manufacture of a medicament for treating a CLDN18.2-expressing cancer.

Images